прополис对阿尔茨海默氏症模型小鼠认知衰退的预防作用
Ryo Inagaki1, Tohru Yamakuni2, Takashi Saito3
1Research Center for Pharmaceutical Development, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
Neurobiology of aging
|April 7, 2024
概括
巴西绿色在阿尔茨海默病方面表现有前途,通过激活信号通路,改善年轻小鼠的认知功能和海马体潜能.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特点是认知能力下降.
- 巴西绿色是一种具有潜在治疗功能的天然化合物.
- 细胞内 ([Ca2+]i) 信号传递在神经元功能和认知过程中起着至关重要的作用.
研究的目的:
- 在阿尔茨海默病小鼠模型中研究巴西绿色的治疗潜力.
- 探索 прополис对认知缺陷和海马长期潜能 (LTP) 的影响.
- 阐明细胞内信号在介导神经保护中的作用.
主要方法:
- 使用Neuro-2A细胞来评估产生的细胞内 ([Ca2+]i) 变化.
- APP-KI小鼠 (阿尔茨海默病的模型) 和WT小鼠接受了行为任务来评估记忆.
- 在施用后,分析了CA1区域的海马体LTP和信号通路.
主要成果:
- 在Neuro-2A细胞中,诱导了细胞内 ([Ca2+]i) 的暂时增加.
- 施用 (300-1000毫克/公斤/天8周) 显著改善了4个月大的APP-KI小鼠的认知缺陷.
- 改善了海马的LTP,并激活了年轻APP-KI小鼠的CA1区域的细胞内信号通路.
结论:
- 巴西绿色石在阿尔茨海默病早期阶段的小鼠模型中显示出对认知衰退的预防作用.
- 的治疗效益与细胞内信号通路的调节有关.
- 蜂可能是阿尔茨海默氏症早期干预策略的可行剂.
更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.3K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
相关概念视频
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
